Prenatal genetic screening

Online Journal of Issues in Nursing

Volumn 5, Issue 3, 2000, Pages 22-44

  Grant, Stanley S ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

AFP; Down syndrome; False positive; Neural tube defect; Screening

Indexed keywords

ANAMNESIS; BIRTH DEFECT; CHROMOSOME ABERRATION; DOWN SYNDROME; EMPLOYMENT; EVALUATION; FEMALE; FETUS; FOLLOW UP; GENETIC SCREENING; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NEURAL TUBE DEFECT; NURSE; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; PSYCHOLOGICAL ASPECT; REVIEW; SAMPLING; SERUM; ULTRASOUND; WELLBEING;

EID: 3843063725     PISSN: 10913734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Abuelo, D. N., Hopmann, M. R., Barsel-Bowers, G., & Goldstein, A. (1991). Anxiety in women with low maternal serum alpha-fetoprotein screening results. Prenatal Diagnosis, 11, 381-385.
2. Aitken, D.A. Wallace, E. M., Crossley, J. A., Swanston, I.A., Pareren, Y.V., Maarle, M. V., Groome, N. P., Macri, J. N., & Connor, J. M. (1996). Dimeric Inhibin A as a marker for Down's syndrome in early pregnancy. New England Journal of Medicine, 334: 1231-6.
3. Armitage, P., & Colton, T. (eds.) (1998). Encyclopedia of Biostatistics Volume 5. Boston: John Wiley & Sons.
4. Bahado-Singh, R., Ozgur, D., Oz, U., Tan, A., Hunter, D., Copel, J., & Mahoney, M. J. (1998). An alternative for women initially declining genetic amniocentesis: Individual Down syndrome odds on the basis of maternal age and multiple ultrasonographic markers. American Journal of Obstetrics and Gynecology, 179: 514-9.
5. Bogart, M. H., Pandian, M. R., & Jones, O. W. (1987). Abnormal maternal serum chorionic gonadotrophin levels in pregnancies with fetal chromosome abnormalities. Prenatal Diagnosis, 7, 197-199.
6. Braithwaite, J. M., Kadir, R. A., Pepera, T. A., Morris, R. W., Thompson, P. J., & Eonomides, D. L. (1996). Nuchal translucency measurement: training of potential examiners. Ultrasound in Obstetrics and Gynecology, 8,3,192-5.
7. Brock, D. J., & Sutcliffe, R. G. (1972). Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 2, 770, 197-199.
8. Burton, B. K. (1988). Elevated Maternal Serum Alpha-Fetoprotein (MSAFP): Interpretation and Follow-up. In R. M. Pitkin, Jr. & J. R. Scott (eds), Clinical Obstetrics and Gynecology, 31, 293-205.
9. Canick, J. A., Knight, G. J., Palomaki, G. E., Haddow, J.E., Cuckle, H. S., & Wald, N. J. (1988). Low second trimester maternal serum unconjugated oestriol in pregnancies with Down syndrome. British Journal of Obstetrics and Gynecology, 95, 330-333.
10. Czeizel, A. E., & Dudas, I. (1992). Prevention of the first occurrence of neural tube defects by periconceptual vitamin supplementation. The New England Journal of Medicine, 119, 327,1832-5.
11. Croyle, R. T. (1995). Introduction. In R.T. Croyle (ed). Psychosocial Effects of Screening for Disease Prevention and Detection, (pp. 3-7).
12. Cuckle, H. S., Holding, S., Jones, R., Groome, N. P., & Wallace, E. M. (1996). Combining Inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenatal Diagnosis, 16: 1095-1100.
13. Duster, T. (1990). The genetic screening of target populations. In Backdoor to Eugenics. New York: Routledge.
14. Dweyer, J. M., (1983). Scientific criteria for adopting health screening measures. Pediatric Nursing, May/June, 195-197.
15. Evans, M. I., Bottoms, S. F., Carlucci, T., Grant, J., Belsky, R. L., Solyom, A. E., Quigg, M. H., & LaFerla, J. J. (1988). Determinants of altered anxiety after abnormal maternal serum fetoprotein screening. American Journal of Obstetrics and Gynecology, 159: 1501-4.
16. Farrant, W. (1985). Who's for amniocentesis? The politics of prenatal screening. In H. Homans (ed,) The Sexual Politics of Reproduction. London: Gower. (pp. 96-177).
17. Filly, R. A. (2000). Obstetrical sonography: The best way to terrify a pregnant woman. Journal of Ultrasound in Medicine, 19, 1-5.
18. Fitzgerald, J., Streets, K., & Priest, J., (1992). Maternal serum screening risk for Down syndrome is considered positive if a triple-maker-derived risk exceeds the age-specific risk: Use of this definition for women aged 35 and over. Prenatal Diagnosis, 13, 2, 152-153.
19. Green, J. M. (1990). Prenatal screening and diagnosis: Some psychological and social issues. British Journal of Obstetrics and Gynecology, 97, 1074-1076.
20. Green, J. M., & Statham, H. (1999). Psychosocial aspects of prenatal screening and diagnosis. In T. Marteau and M. Richards (eds) The Troubled Helix: Social and Psychological Implications Of The New Human Genetics. New York: Cambridge. (pp.140-163).
21. Haddow, J. E., Palomaki, G. E., Knight, G. J., Williams, J., Pulkkinen, A., Canick, J. A., Saller, Jr., D. N., & Barsel Bowers, G. (1992). Prenatal screening for Down sydrome with the use of maternal serum markers. New England Journal of Medicine, 327, 588-593.
22. Haddow, J. E., Palomaki, G. E., Knight, G. J., Williams, J., Miller, W. A., & Johnson, A. (1998). Screening of maternal serum for fetal Down's syndrome in the first trimester. New England Journal of Medicine, 338, 955-961.
23. Hall, S., Bobrow, M., & Marteau, T. M., (2000). Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study. British Medical Journal, 320: 407-412.
24. Kalter, H., & Warkany J. (1983a). Medical Progress. Congenital malformations: etiologic factors and their role in prevention. Part I. New England Journal of Medicine. 308 (8): 424-1.
25. Kalter, H., & Warkany J. (1983b). Medical Progress. Congenital malformations: etiologic factors and their role in prevention. Part II. New England Journal of Medicine. 308 (9): 491-7.
26. Lashley (Cohen), F. R., (1998). Prenatal detection and diagnosis. In Clinical Genetics in Nursing Practice. (pp. 271-293). New York: Springer Publishing Company.
27. Lennon, C. A., & Gray, D. L. (1999). Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstetrics and Gynecology, 94, 562-566.
28. Main, D. M., & Mennuti, M. T., (1986). Neural tube defects: issues in prenatal diagnosis and counseling. Obstetrics and Gynecology, 67, 1-16.
29. Marteau, T. M. (1989). Psychological costs of screening. British Medical Journal, 299, 527.
30. Marteau, T. M., Johnston, M., Kidd, J., Michie, S., Cook, R., Slack, J., & Shaw, R. W. (1992). Psychological models in predicting uptake of prenatal screening. Psychology and Health, 6, 13-22.
31. Medical Research Council Vitamin Study Research Group (1991). Preventions of neural tube defects: Results of the Medical Research Council vitamin study. Lancet, 338; 1131-37.
32. Merkatz, I. R., Nitowsky, J. M., Macri, J. N., & Johnson, W. E., (1984). An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. American Journal of Obstetrics and Gynecology, 148,7, 886-894.
33. Nicolaides, K. H., Azar, G., Byrne, D., Mansur, C., & Marks, K. (1992). Fetal nuchal translucency: Ultrasound screening for chromosomal defects in the first trimester of pregnancy. British Medical Journal, 304, 867-869.
34. Nicolaides, K. H., Sebire, N. J., & Snijdes, J. M. (1999). Nuchal translucency and chromosomal defects. In The 11-14 Week Scan. New York: Parthenon. (p.41).
35. Oakley, G. P., Adams, M. J., & Dickinson, C. M. (1996). More folic acid for everyone, now. Journal of Nutrition, 126: 751S-755S.
36. O'Connor, M. A. (1997). Fetal maternal case management. Nursing Case Management, 2: 55-67.
37. Palomaki, G. E. (1986). Collaborative study of Down syndrome screening using maternal serum alpha-fetoprotein and maternal age. The Lancet, December 10-27. 1460.
38. Palomaki, G. E., Williams, J., & Haddow, J. E. (1989). New England regional genetics group prenatal collaborative study of Down syndrome screening: Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. American Journal of Obstetrics and Gynecology, 160; 578-581.
39. Palomaki, G. E., Knight, G. J., McCarthy, J. E., Haddow, J. E., & Donhowe, J. M. (1997). Maternal serum screening for Down syndrome in the United States: A 1995 survey. American Journal of Obstetrics and Gynecology, 176; 1046-1051.
40. Rankin, J., Dillon, E., & Wright, C. (1999). Congenital anterior abdominal wall defects in the north of England, 1986-1996: occurrence and outcome. Prenatal Diagnosis, 19 (7): 662-8.
41. Shulman, L. P., Emerson, D., Felker, R., Phillips, O., Simpson, J., & Elias, S. (1992). High frequency of cytogenetic abnormalities with cystic hygroma diagnosed in the first trimester. Obstetrics and Gynecology, 80(1): 80-2.
42. Scanlon, C. S. & Fibison, W. (1995). Managing Genetic Information: Implications for Nursing Practice. Washington, DC. American Nurses Publishing.
43. Tymstra, T. (1991). Prenatal diagnosis, prenatal screening and the rise of the tentative pregnancy. International Journal of Technology Assessment in Health Care, 7: 4, 509-516.
44. Vintzileos, A. M., Guzman, E. R., Smulian, J. C., Mclean, D. A., & Ananth, C. V. (1997). Choice of second-trimester genetic sonogram for detection of trisomy 21. Obstetrics and Gynecology, 90: 187-90.
45. Vintzileos, A. M., Guzman, E. R., Smulian, J. C., Day-Salvatore, D. L., & Knuppel, R. A. (1999). Indication-specific accuracy of second trimester genetic ultrasonography for the detection of trisomy 21. American Journal of Obstetrics and Gynecology, 181, 1045-1048.
46. Wald, N. J., Cuckle, H. S., Densem, J. W., Nanchalhal, K., Royston, P., Chard, T., Haddow, J. E., Knight, G. E., Palomaki, G. E., & Canick, J. A. (1988). Maternal serum screening for Down's Syndrome in early pregnancy. British Medical Journal, 297, 883-887.
47. Wright, L. (1994). Prenatal diagnosis in the 1990's. Journal of Obstetric, Gynecologic and Neonatal Nursing, 23; 506-515.